The law firm of Glassman, Edwards, Wade & Wyatt announces that Covidien Ltd. is recalling 471,000 disposable insulin syringes because of mislabeling that could cause patients to receive an overdose. The labeling error could be deadly.

The FDA urged patients and health-care professionals to check syringe packaging carefully for syringes labeled as “100 units for use with U-100 insulin” that were made in lot number 813900. Syringes were sold at Wal-Mart and Sam’s Club stores. You can read more in the FDA release HERE.

If you have been injured because of the Covidien Ltd. recall, please call Ed Wallis today at (901) 527-2125, or send Ed an email today by clicking HERE.

The agreements bring to a close the department’s industrywide investigation into the problems of rescission that were brought to light in a series of articles in The L.A. Times. The problem affects individual policies, the type of coverage consumers without access to employer-sponsored group health benefits purchase on their own. About 14 million Americans, including 3 million Californians, rely on this type of coverage.

You can read more HERE in the L.A. Times.